HRP20110550T1 - Derivati 7-alkinil-1,8-naftiridinona, njihovo dobivanje i njihova upotreba u terapiji - Google Patents

Derivati 7-alkinil-1,8-naftiridinona, njihovo dobivanje i njihova upotreba u terapiji Download PDF

Info

Publication number
HRP20110550T1
HRP20110550T1 HR20110550T HRP20110550T HRP20110550T1 HR P20110550 T1 HRP20110550 T1 HR P20110550T1 HR 20110550 T HR20110550 T HR 20110550T HR P20110550 T HRP20110550 T HR P20110550T HR P20110550 T1 HRP20110550 T1 HR P20110550T1
Authority
HR
Croatia
Prior art keywords
compound
formula
accordance
cancer
preparation
Prior art date
Application number
HR20110550T
Other languages
English (en)
Croatian (hr)
Inventor
Alam Antoine
Bono Fran�oise
Duclos Olivier
Mc Cort Gary
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of HRP20110550T1 publication Critical patent/HRP20110550T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
HR20110550T 2007-06-13 2008-06-11 Derivati 7-alkinil-1,8-naftiridinona, njihovo dobivanje i njihova upotreba u terapiji HRP20110550T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0704193A FR2917413B1 (fr) 2007-06-13 2007-06-13 Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
PCT/FR2008/000794 WO2009007536A2 (fr) 2007-06-13 2008-06-11 Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique

Publications (1)

Publication Number Publication Date
HRP20110550T1 true HRP20110550T1 (hr) 2011-09-30

Family

ID=38961501

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110550T HRP20110550T1 (hr) 2007-06-13 2008-06-11 Derivati 7-alkinil-1,8-naftiridinona, njihovo dobivanje i njihova upotreba u terapiji

Country Status (28)

Country Link
US (2) US8263614B2 (enrdf_load_html_response)
EP (1) EP2158194B1 (enrdf_load_html_response)
JP (1) JP5346337B2 (enrdf_load_html_response)
KR (1) KR20100019507A (enrdf_load_html_response)
CN (1) CN101815715B (enrdf_load_html_response)
AR (1) AR066955A1 (enrdf_load_html_response)
AT (1) ATE509923T1 (enrdf_load_html_response)
AU (1) AU2008274100B2 (enrdf_load_html_response)
BR (1) BRPI0813809B1 (enrdf_load_html_response)
CA (1) CA2690349C (enrdf_load_html_response)
CO (1) CO6150157A2 (enrdf_load_html_response)
CY (1) CY1111748T1 (enrdf_load_html_response)
DK (1) DK2158194T3 (enrdf_load_html_response)
EA (1) EA016552B1 (enrdf_load_html_response)
ES (1) ES2366629T3 (enrdf_load_html_response)
FR (1) FR2917413B1 (enrdf_load_html_response)
HR (1) HRP20110550T1 (enrdf_load_html_response)
IL (1) IL202677A (enrdf_load_html_response)
IN (1) IN2009KN04279A (enrdf_load_html_response)
MA (1) MA31674B1 (enrdf_load_html_response)
ME (1) ME00957B (enrdf_load_html_response)
MX (1) MX2009013514A (enrdf_load_html_response)
MY (1) MY146939A (enrdf_load_html_response)
NZ (1) NZ581883A (enrdf_load_html_response)
PL (1) PL2158194T3 (enrdf_load_html_response)
PT (1) PT2158194E (enrdf_load_html_response)
SI (1) SI2158194T1 (enrdf_load_html_response)
WO (1) WO2009007536A2 (enrdf_load_html_response)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2917412B1 (fr) * 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
AU2008335772B2 (en) 2007-12-10 2014-11-27 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3- methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1- (2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2954943B1 (fr) * 2010-01-07 2013-03-01 Sanofi Aventis Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
FR2955109B1 (fr) * 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
WO2012009097A1 (en) * 2010-06-17 2012-01-19 Cytokinetics, Inc. Methods of treating lung disease
WO2013072882A1 (en) * 2011-11-18 2013-05-23 Actelion Pharmaceuticals Ltd 2 -amino- 1, 8 -naphthyridine-3 -carboxamide derivatives as antimicrobial agents
CN116509854B (zh) * 2023-04-26 2025-05-23 浙江省中医院、浙江中医药大学附属第一医院(浙江省东方医院) 一种萘啶酮衍生物的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9800921A (es) 1995-08-02 1998-05-31 Chirotech Technology Ltd Quinolonas y su uso terapeutico.
WO1999038867A1 (fr) 1998-01-29 1999-08-05 Suntory Limited Derives de 1-cycloalkyle-1,8-naphthyridine-4-one presentant une activite inhibitrice de la phosphodiesterase iv
DE19826050A1 (de) * 1998-06-12 1999-12-16 Bayer Ag Verfahren zur Herstellung von Chinolon- und Naphthyridoncarbonsäuren und deren Ester
IL158783A0 (en) 2001-05-08 2004-05-12 Schering Ag Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
CA2447765C (en) 2001-05-24 2011-01-25 Merck Frosst Canada & Co./Merck Frosst Canada & Cie 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
US7148357B2 (en) 2002-07-31 2006-12-12 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
EP1761539A1 (en) * 2004-06-02 2007-03-14 Takeda Pharmaceutical Company Limited Indole derivative and use for treatment of cancer
FR2917412B1 (fr) * 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
IL202677A0 (en) 2010-06-30
KR20100019507A (ko) 2010-02-18
MX2009013514A (es) 2010-01-27
MA31674B1 (fr) 2010-09-01
AU2008274100B2 (en) 2013-07-11
CN101815715B (zh) 2014-10-08
DK2158194T3 (da) 2011-09-12
BRPI0813809B1 (pt) 2021-05-25
ES2366629T3 (es) 2011-10-24
AR066955A1 (es) 2009-09-23
CY1111748T1 (el) 2015-10-07
CA2690349C (fr) 2015-11-24
JP2010529179A (ja) 2010-08-26
EA016552B1 (ru) 2012-05-30
FR2917413B1 (fr) 2009-08-21
WO2009007536A3 (fr) 2009-03-19
SI2158194T1 (sl) 2011-10-28
EA201070010A1 (ru) 2010-06-30
ATE509923T1 (de) 2011-06-15
AU2008274100A1 (en) 2009-01-15
CO6150157A2 (es) 2010-04-20
NZ581883A (en) 2011-05-27
US20120238598A1 (en) 2012-09-20
US8586602B2 (en) 2013-11-19
IN2009KN04279A (enrdf_load_html_response) 2015-08-28
HK1143590A1 (en) 2011-01-07
WO2009007536A2 (fr) 2009-01-15
IL202677A (en) 2014-12-31
ME00957B (me) 2012-06-20
EP2158194A2 (fr) 2010-03-03
MY146939A (en) 2012-10-15
WO2009007536A8 (fr) 2010-01-07
EP2158194B1 (fr) 2011-05-18
US20100144782A1 (en) 2010-06-10
PT2158194E (pt) 2011-08-17
CA2690349A1 (fr) 2009-01-15
CN101815715A (zh) 2010-08-25
BRPI0813809A2 (pt) 2020-02-04
US8263614B2 (en) 2012-09-11
JP5346337B2 (ja) 2013-11-20
FR2917413A1 (fr) 2008-12-19
PL2158194T3 (pl) 2011-10-31

Similar Documents

Publication Publication Date Title
HRP20110550T1 (hr) Derivati 7-alkinil-1,8-naftiridinona, njihovo dobivanje i njihova upotreba u terapiji
HRP20110515T1 (hr) Derivati 7-alkinil-1,8-naftiridinona, njihovo dobivanje i njihova upotreba u terapiji
HRP20140611T1 (hr) Inhibitori kinaze p70 s6
ME02892B (me) Hemijska jedinjenja
TNSN07164A1 (en) Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
NZ605528A (en) Ip receptor agonist heterocyclic compounds
EP1073656A1 (en) Imidazo pyridine derivatives which inhibit gastric acid secretion
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
NZ590784A (en) Pyrazolopyridine kinase inhibitors
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
JP2016504365A5 (enrdf_load_html_response)
ME00158B (me) Pirimidini supstituisani sulfoksiiminima kao cdk-i/ili vegf-inhibitori, njihovo dobijanje i primjena kao lijeka
IL175716A (en) 2- (4-Bromo- or 4-Methyl-Phenylamino) -6-Oxo-1,6-Dihydropyridines and their use in drug preparation
MEP23808A (en) Pyridine[3,4-b]pyrazinones
CA2548654A1 (en) Piperidine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication
HRP20160030T1 (hr) Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace)
HRP20200632T1 (hr) Derivati piridopirazina i naftiridina za liječenje raka
WO2019165043A3 (en) Indane-amines as pd-l1 antagonists
JP2005505618A5 (enrdf_load_html_response)
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
HRP20170695T1 (hr) Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka
HRP20191826T4 (hr) Derivati n-piridinil acetamida kao inhibitori wnt signalnog puta
NO20030624L (no) Cinnolinforbindelser
PH12019500804A1 (en) Liposomal formulation for use in the treatment of cancer
HRP20192279T1 (hr) Novi spojevi imidazopiridazina i njihova uporaba